Skip to content
drillr.ai

FDMT

4D Molecular Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$11.09+0.91%

Price as of Jul 20, 2026

FDMT news

4D Molecular Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

    * After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years  * 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transf

    Globe Newswire ·

  2. 4DMT Announces New Employment Inducement Grants

    EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 14, 2026, the compensation committee of the Company’s board of directors granted six new non-executive employees 37,900 Restricted Stock Units (RSUs). The RSUs wer

    Globe Newswire ·

  3. 4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

    EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44(th) Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Montreal, Canada, from July 15 - 18, 2026. ASR

    Globe Newswire ·

  4. Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

    ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of August Moretti to its board of directors. Concurrent with this appointment, the Company announced the retirement of Dr. Dean Baker from the board. “We are pleased to welcome August Moretti to our board at this transformative stage for Vivani,” said G

    Globe Newswire ·

  5. 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

    * Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 * PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and SPECTRA DME trial 2-year data in H2 2026 * 4D-150 DME global Phase 3 trial initiation expected in Q3 2026 * $514 million in cash, cash equivalents and marketable securities expected to fund current operating plan int

    Globe Newswire ·